Founded in 2002, Dune Medical Devices envisions improving the performance and outcomes of a broad range of diagnostic and therapeutic procedures through the application of its tissue characterization technology to providing a real-time indication of a tissue's pathologic status.

Dune's initial focus has been surgical oncology, where it is engaged in the development and commercialization of intra-operative systems intended to identify cancerous tissues, thereby enabling immediate removal and cancer-free surgical results. In June 2006, Dune received CE marking for its first commercial application, the MarginProbe™ system, which is intended for use in breast cancer surgery.

Dune Medical Devices is a privately-held company. It has offices in New York, Israel, and Switzerland.